In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs
Abstract
:1. Introduction
2. Results
2.1. HIV Isolates Characteristics
2.2. Screening for Antiretroviral Drugs
3. Discussion
4. Materials and Methods
4.1. HIV Isolates
4.2. Growth Capability Assessment
4.3. Drug-Induced Cytotoxicity Assay
4.4. Evaluation of Drug Response
4.5. Evaluation of Antiretroviral Susceptibility
4.6. RNA Extraction and Polymerase Chain Reaction
4.7. HIV Pol Region Nucleotide Sequences and Genotyping
4.8. HIV V3 Region Nucleotide Sequences and Coreceptor Prediction
4.9. Data Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- UNAIDS Global HIV & AIDS Statistics—Fact Sheet. Available online: https://www.unaids.org/en/resources/fact-sheet (accessed on 26 April 2021).
- Avert Global HIV and Aids Statistics. Available online: https://www.avert.org/global-hiv-and-aids-statistics (accessed on 26 April 2021).
- Pozniak, A.L.; Hill, A.M. First-Line Integrase Inhibitors for HIV—Prices versus Benefits. Lancet HIV 2016, 3, e500–e501. [Google Scholar] [CrossRef]
- WHO. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available online: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/what-start-initial-combination-regimens-antiretroviral-naive?view=full (accessed on 26 April 2021).
- WHO. Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV—Interim Guidance. Available online: https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51 (accessed on 26 April 2021).
- Saag, M.S.; Gandhi, R.T.; Hoy, J.F.; Landovitz, R.J.; Thompson, M.A.; Sax, P.E.; Smith, D.M.; Benson, C.A.; Buchbinder, S.P.; del Rio, C.; et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA 2020, 324, 1651–1669. [Google Scholar] [CrossRef] [PubMed]
- Nega, J.; Taye, S.; Million, Y.; Rodrigo, C.; Eshetie, S. Antiretroviral Treatment Failure and Associated Factors among HIV Patients on First-Line Antiretroviral Treatment in Sekota, Northeast Ethiopia. AIDS Res. Ther. 2020, 17, 39. [Google Scholar] [CrossRef] [PubMed]
- Sheldon, J.; Beach, N.M.; Moreno, E.; Gallego, I.; Pineiro, D.; Martinez-Salas, E.; Gregori, J.; Quer, J.; Esteban, J.I.; Rice, C.M.; et al. Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus. J. Virol. 2014, 88, 12098–12111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Babo, Y.D.; Alemie, G.A.; Fentaye, F.W. Predictors of First-Line Antiretroviral Therapy Failure amongst HIV-Infected Adult Clients at Woldia Hospital, Northeast Ethiopia. PLoS ONE 2017, 12, e0187694. [Google Scholar] [CrossRef] [Green Version]
- Hogan, C.M.; Hammer, S.M. Host Determinants in HIV Infection and Disease Part 1: Cellular and Humoral Immune Responses. Ann. Intern. Med. 2001, 134, 761–776. [Google Scholar] [CrossRef]
- Selhorst, P.; Combrinck, C.; Ndabambi, N.; Ismail, S.D.; Abrahams, M.; Lacerda, M.; Samsunder, N.; Garrett, N.; Karim, Q.A.; Karim, S.S.A.; et al. Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression. J. Virol. 2017, 91, e01806-16. [Google Scholar] [CrossRef] [Green Version]
- McCluskey, S.M.; Siedner, M.J.; Marconi, V.C. Management of Virologic Failure and HIV Drug Resistance. Infect. Dis. Clin. N. Am. 2019, 33, 707–742. [Google Scholar] [CrossRef]
- Kyeyune, F.; Nankya, I.; Metha, S.; Akao, J.; Ndashimye, E.; Tebit, D.M.; Rodriguez, B.; Kityo, C.; Salata, R.A.; Mugyenyi, P.; et al. Treatment Failure and Drug Resistance Is More Frequent in HIV-1 Subtype D versus Subtype A-Infected Ugandans over a 10-Year Study Period. AIDS 2013, 27, 1899. [Google Scholar] [CrossRef] [Green Version]
- Kahn, T.R.; Desmond, M.; Rao, D.; Marx, G.E.; Guthrie, B.L.; Bosire, R.; Choi, R.Y.; Kiarie, J.N.; Farquhar, C. Delayed Initiation of Antiretroviral Therapy among HIV-Discordant Couples in Kenya. AIDS Care 2013, 25, 265–272. [Google Scholar] [CrossRef]
- Dykes, C.; Demeter, L.M. Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 2007, 20, 550–578. [Google Scholar] [CrossRef] [Green Version]
- Kageyama, S.; Amolong Hinay, A.; Telan, E.F.O.; Samonte, G.M.J.; Leano, P.S.A.; Tsuneki-Tokunaga, A.; Kanai, K. Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines. J. Int. Assoc. Provid. AIDS Care 2019, 18, 1–8. [Google Scholar] [CrossRef]
- Martinez-Picado, J.; Deeks, S.G. Persistent HIV-1 Replication during Antiretroviral Therapy. Curr. Opin. HIV AIDS 2016, 11, 417. [Google Scholar] [CrossRef]
- Nachega, J.B.; Hislop, M.; Dowdy, D.W.; Chaisson, R.E.; Regensberg, L.; Maartens, G. Adherence to Nonnucleoside Reverse Transcriptase Inhibitor-Based HIV Therapy and Virologic Outcomes. Ann. Intern. Med. 2007, 146, 564–573. [Google Scholar] [CrossRef]
- Shafer, R.W. Rationale and Uses of a Public HIV Drug-Resistance Database. J. Infect. Dis. 2006, 194 (Suppl. S1), S51–S58. [Google Scholar] [CrossRef] [Green Version]
- Pau, A.K.; George, J.M. Antiretroviral Therapy: Current Drugs. Infect. Dis. Clin. N. Am. 2014, 28, 371–402. [Google Scholar] [CrossRef] [Green Version]
- Li, J.Z.; Paredes, R.; Ribaudo, H.J.; Svarovskaia, E.S.; Metzner, K.J.; Kozal, M.J.; Hullsiek, K.H.; Balduin, M.; Jakobsen, M.R.; Geretti, A.M.; et al. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis. JAMA J. Am. Med. Assoc. 2011, 305, 1327–1335. [Google Scholar] [CrossRef] [Green Version]
- Tang, M.W.; Kanki, P.J.; Shafer, R.W. A Review of the Virological Efficacy of the 4 World Health Organization-Recommended Tenofovir-Containing Regimens for Initial HIV Therapy. Clin. Infect. Dis. 2012, 54, 862–875. [Google Scholar] [CrossRef] [Green Version]
- Wassner, C.; Bradley, N.; Lee, Y. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. J. Int. Assoc. Provid. AIDS Care 2020, 19, 1–10. [Google Scholar] [CrossRef] [Green Version]
- CDC. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available online: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/virologic-failure?view=full (accessed on 2 December 2021).
- Callebaut, C.; Stepan, G.; Tian, Y.; Miller, M.D. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. Antimicrob. Agents Chemother. 2015, 59, 5909–5916. [Google Scholar] [CrossRef]
- Hill, A.; Hughes, S.L.; Gotham, D.; Pozniak, A.L. Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate: Is There a True Difference in Efficacy and Safety? J. Virus Erad. 2018, 4, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Stanford University. Major HIV-1 Drug Resistance Mutations. Available online: https://hivdb.stanford.edu/ (accessed on 26 April 2022).
- Margot, N.; Liu, Y.; Babusis, D.; Miller, M.D.; Callebaut, C. Antiviral Activity of Tenofovir Alafenamide (TAF) against Major NRTI-Resistant Viruses: Improvement over TDF/TFV Is Driven by Higher TFV-DP Loading in Target Cells. In Proceedings of the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Toronto, ON, Canada, 4–8 June 2013. [Google Scholar]
- Tao, X.; Lu, Y.; Zhou, Y.; Zhang, L.; Chen, Y. Efficacy and Safety of the Regimens Containing Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in Fixed-Dose Single-Tablet Regimens for Initial Treatment of HIV-1 Infection: A Meta-Analysis of Randomized Controlled Trials. Int. J. Infect. Dis. 2020, 93, 108–117. [Google Scholar] [CrossRef] [PubMed]
- Zhang, K.; Zhang, Y.; Liu, X.; Li, A.; Gao, M.; Hou, J.; Guo, C.; Zhang, T.; Wu, H.; Chen, G.; et al. Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis. Front. Pharmacol. 2021, 12, 603068. [Google Scholar] [CrossRef] [PubMed]
- World Health Organisation (WHO). Policy Brief: Update of Recommendations on First-and Second-Line Antiretroviral Regimens. WHO Libr. Cat. Data. Available online: https://apps.who.int/iris/handle/10665/325892 (accessed on 23 April 2021).
- Hightower, K.E.; Wang, R.; DeAnda, F.; Johns, B.A.; Weaver, K.; Shen, Y.; Tomberlin, G.H.; Carter, H.L.; Broderick, T.; Sigethy, S.; et al. Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes. Antimicrob. Agents Chemother. 2011, 55, 4552–4559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wood, R. Atazanavir: Its Role in HIV Treatment. Expert Rev. Anti. Infect. Ther. 2008, 6, 785–796. [Google Scholar] [CrossRef] [Green Version]
- Rivas, P.; Morello, J.; Garrido, C.; Rodríguez-Nóvoa, S.; Soriano, V. Role of Atazanavir in the Treatment of HIV Infection. Ther. Clin. Risk Manag. 2009, 5, 99. [Google Scholar]
- Pan, H.; Lu, P.; Shen, Y.; Wang, Y.; Jiang, Z.; Yang, X.; Zhong, Y.; Yang, H.; Khan, I.U.; Zhou, M.; et al. The Bromodomain and Extraterminal Domain Inhibitor Bromosporine Synergistically Reactivates Latent HIV-1 in Latently Infected Cells. Oncotarget 2017, 8, 94104. [Google Scholar] [CrossRef] [Green Version]
- Ray, A.S.; Fordyce, M.W.; Hitchcock, M.J.M. Tenofovir Alafenamide: A Novel Prodrug of Tenofovir for the Treatment of Human Immunodeficiency Virus. Antiviral Res. 2016, 125, 63–70. [Google Scholar] [CrossRef] [Green Version]
- University of LIVERPOOL. HIV Drug Interactions. Available online: https://www.hiv-druginteractions.org/ (accessed on 21 September 2021).
- Nii-Trebi, N.I.; Ibe, S.; Barnor, J.S.; Ishikawa, K.; Brandful, J.A.M.; Ofori, S.B.; Yamaoka, S.; Ampofo, W.K.; Sugiura, W. HIV-1 Drug-Resistance Surveillance among Treatment-Experienced and -Naïve Patients after the Implementation of Antiretroviral Therapy in Ghana. PLoS ONE 2013, 8, e71972. [Google Scholar] [CrossRef]
- Fabeni, L.; Berno, G.; Fokam, J.; Bertoli, A.; Alteri, C.; Gori, C.; Forbici, F.; Takou, D.; Vergori, A.; Pennica, A.; et al. Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. J. Clin. Microbiol. 2017, 55, 2827–2837. [Google Scholar] [CrossRef] [Green Version]
- McGovern, R.A.; Richard Harrigan, P.; Swenson, L.C. Genotypic Inference of HIV-1 Tropism Using Population-Based Sequencing of V3. J. Vis. Exp. 2010, 46, e2531. [Google Scholar] [CrossRef] [PubMed]
- The Los Alamos HIV Sequence HIV Sequence Locator. Available online: https://www.hiv.lanl.gov/content/index (accessed on 15 June 2022).
- Chan, C.N.; Trinité, B.; Levy, D.N. Potent Inhibition of HIV-1 Replication in Resting CD4 T Cells by Resveratrol and Pterostilbene. Antimicrob. Agents Chemother. 2017, 61, e00408-17. [Google Scholar] [CrossRef] [PubMed]
Strain ID | Amount of HIV-RNA (×106 Copies/mL) in | Drug Resistance-Related Mutation c | Genotype | Coreceptor Usage d | Accession Number | |
---|---|---|---|---|---|---|
Culture Sup a | Plasma b | |||||
DR1509-397 | 2000 | 1.6 | None | CRF01_AE | CXCR4 | ON229916 |
DR1606-521 | 340 | 1.7 | EFV, FTC, TDF, 3TC | CRF01_AE | CXCR4 | ON229919 |
DR1510-726 | 300 | 7.8 | EFV, FTC, TDF, 3TC | CRF01_AE | CXCR4 | ON229920 |
DR1605-400 | 230 | 0.74 | None | CRF01_AE | CXCR4 | ON229917 |
DR1606-479 | 180 | 5.1 | EFV, FTC, TDF, 3TC | CRF01_AE | CXCR4 | ON229921 |
S1506-064 | 100 | Not done | ZDV | Subtype B | CXCR4 | ON229918 |
DR1606-559 | 9.7 | 5.6 | EFV | CRF01_AE | CCR5 | ON229922 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hinay, A.A., Jr.; Kanai, K.; Tsuneki-Tokunaga, A.; Komatsu, M.; Telan, E.O.; Kageyama, S. In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs. Int. J. Mol. Sci. 2022, 23, 15380. https://doi.org/10.3390/ijms232315380
Hinay AA Jr., Kanai K, Tsuneki-Tokunaga A, Komatsu M, Telan EO, Kageyama S. In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs. International Journal of Molecular Sciences. 2022; 23(23):15380. https://doi.org/10.3390/ijms232315380
Chicago/Turabian StyleHinay, Alfredo A., Jr., Kyosuke Kanai, Akeno Tsuneki-Tokunaga, Mizuki Komatsu, Elizabeth O. Telan, and Seiji Kageyama. 2022. "In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs" International Journal of Molecular Sciences 23, no. 23: 15380. https://doi.org/10.3390/ijms232315380